Aldehyde dehydrogenase 2 activation in heart failure restores mitochondrial function and improves ventricular function and remodelling

Cardiovascular Research

Volumn 103, Issue 4, 2014, Pages 498-508

  Gomes, Katia M S ^a   Campos, Juliane C ^a   Bechara, Luiz R G ^a   Queliconi, Bruno ^b   Lima, Vanessa M ^a   Disatnik, Marie Helene ^c   Magno, Paulo ^a   Chen, Che Hong ^c   Brum, Patricia C ^a   Kowaltowski, Alicia J ^b   Mochly Rosen, Daria ^c   Ferreira, Julio C B ^a,c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Instituto de Química   (Brazil)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bioenergetics; Heart disease; Mitochondria; Oxidant stress; Pharmacological therapy

Indexed keywords

4 HYDROXYNONENAL; ALDEHYDE DEHYDROGENASE ISOENZYME 2; CYTOCHROME C; HYDROGEN PEROXIDE; MITOCHONDRIAL ALDEHYDE DEHYDROGENASE 2 ACTIVATOR; OXIDOREDUCTASE INHIBITOR; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ALDEHYDE DEHYDROGENASE; ALDH2 PROTEIN, RAT; MITOCHONDRIAL PROTEIN; CALCIUM ION; CARBONYL DERIVATIVE; ISOPRENALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE COMPLIANCE; HEART MUSCLE FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATION CONTROL; ANIMAL; CARDIAC MUSCLE CELL; ENZYMOLOGY; HEART CONTRACTION; METABOLISM; MITOCHONDRION; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT; HEART MUSCLE CELL; TREATMENT DURATION;

ALDEHYDE DEHYDROGENASE; ANIMALS; HEART FAILURE; MALE; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; MYOCARDIAL CONTRACTION; MYOCYTES, CARDIAC; RATS, WISTAR; VENTRICULAR FUNCTION; VENTRICULAR REMODELING;

EID: 84907362886     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu125     Document Type: Article

References (37)

1. Gerczuk PZ, Kloner RA. An update on cardioprotection: a reviewof the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol 2012;59: 969-978.
2. Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012;125: e2-e220.
3. Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D. Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science 2008; 321: 1493-1495.
4. Chen CH, Sun L, Mochly-Rosen D. Mitochondrial aldehyde dehydrogenase and cardiac diseases. Cardiovasc Res 2010;88: 51-57.
5. Perez-Miller S, Younus H, Vanam R, Chen CH, Mochly-Rosen D, HurleyTD. Alda-1 is an agonist and chemical chaperone for the common human aldehyde dehydrogenase 2 variant. Nat Struct Mol Biol 2010;17: 159-164.
6. Sun L, Ferreira JC, Mochly-Rosen D. ALDH2 activator inhibits increased myocardial infarction injury by nitroglycerin tolerance. Sci Transl Med 2011;3: 107ra111.
7. Chen CH, Ferreira JC, Gross ER, Mochly-Rosen D. Targeting aldehyde dehydrogenase 2: new therapeutic opportunities. Physiol Rev 2014;94: 1-34.
8. Nakamura K, Kusano K, Nakamura Y, Kakishita M, Ohta K, Nagase S, Yamamoto M, Miyaji K, Saito H, Morita H, Emori T, Matsubara H, Toyokuni S, Ohe T. Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105: 2867-2871.
9. Johns TN, Olson BJ. Experimental myocardial infarction. I. A method of coronary occlusion in small animals. Ann Surg 1954;140: 675-682.
10. Campos JC, Queliconi BB, Dourado PM, Cunha TF, Zambelli VO, Bechara LR, Kowaltowski AJ, Brum PC, Mochly-Rosen D, Ferreira JC. Exercise training restores cardiac protein quality control in heart failure. PLoS ONE 2012;7: e52764.
11. Ferreira JC, Koyanagi T, Palaniyandi SS, Fajardo G, Churchill EN, Budas G, Disatnik MH, Bernstein D, Brum PC, Mochly-Rosen D. Pharmacological inhibition of betaIIPKC is cardioprotective in late-stage hypertrophy. J Mol Cell Cardiol 2011;51: 980-987.
12. Palaniyandi SS, Ferreira JC, Brum PC, Mochly-Rosen D. PKCbetaII inhibition attenuates myocardial infarction induced heart failure and is associated with a reduction of fibrosis and pro-inflammatory responses. J Cell Mol Med 2011;15: 1769-1777.
13. CancheriniDV, Queliconi BB, Kowaltowski AJ. Pharmacological and physiological stimuli do not promote Ca(2+)-sensitive K+ channel activity in isolated heart mitochondria. Cardiovasc Res 2007;73: 720-728.
14. Murphy AN, Bredesen DE, Cortopassi G, Wang E, Fiskum G. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. Proc Natl Acad Sci USA 1996;93: 9893-9898.
15. Bueno CR Jr, Ferreira JC, Pereira MG, Bacurau AV, Brum PC. Aerobic exercise training improves skeletal muscle function and Ca2+ handling-related protein expression in sympathetic hyperactivity-induced heart failure. J Appl Physiol 2010;109: 702-709.
16. Ferreira JC, Boer BN, Grinberg M, Brum PC, Mochly-Rosen D. Protein quality control disruption by PKCbetaII in heart failure; rescue by the selective PKCbetaII inhibitor, betaIIV5-3. PLoS ONE 2012;7: e33175.
17. Budas GR, Disatnik MH, Chen CH, Mochly-Rosen D. Activation of aldehyde dehydrogenase 2 (ALDH2) confers cardioprotection in protein kinase C epsilon (PKCvarepsilon) knockout mice. J Mol Cell Cardiol 2010;48: 757-764.
18. Budas GR, Disatnik MH, Mochly-Rosen D. Aldehyde dehydrogenase 2 in cardiac protection: a new therapeutic target? Trends Cardiovasc Med 2009;19: 158-164.
19. LucasDT, Szweda LI. Cardiac reperfusion injury: aging, lipid peroxidation, and mitochondrial dysfunction. Proc Natl Acad Sci USA 1998;95: 510-514.
20. Petersen DR, Doorn JA. Reactions of 4-hydroxynonenal with proteins and cellular targets. Free Radic Biol Med 2004;37: 937-945.
21. Figueira TR, BarrosMH, Camargo AA, Castilho RF, Ferreira JC, Kowaltowski AJ, Sluse FE, Souza-Pinto NC, Vercesi AE. Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. Antioxid Redox Signal 2013;18: 2029-2074.
22. Kowaltowski AJ, Castilho RF, Vercesi AE. Mitochondrial permeability transition and oxidative stress. FEBS Lett 2001;495: 12-15.
23. RamachandranV, Perez A, Chen J, Senthil D, Schenker S, Henderson GI. In utero ethanol exposure causes mitochondrial dysfunction, which can result in apoptotic cell death in fetal brain: a potential role for 4-hydroxynonenal. Alcohol Clin Exp Res 2001;25: 862-871.
24. Petronilli V, Penzo D, Scorrano L, Bernardi P, Di Lisa F. The mitochondrial permeability transition, release of cytochrome c and cell death. Correlation with the duration of pore openings in situ. J Biol Chem 2001;276: 12030-12034.
25. LeeWC, WongHY, ChaiYY, ShiCW, Amino N, Kikuchi S, Huang SH. Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochem Biophys Res Commun 2012;425: 842-847.
26. Guyatt GH, Devereaux PJ. A review of heart failure treatment. Mt Sinai J Med 2004;71: 47-54.
27. Bayeva M, Gheorghiade M, Ardehali H. Mitochondria as a therapeutic target in heart failure. J Am Coll Cardiol 2012;61: 599-610.
28. Palaniyandi SS, Qi X, Yogalingam G, Ferreira JC, Mochly-Rosen D. Regulation of mitochondrial processes: a target for heart failure. Drug Discov Today Dis Mech 2010;7: e95-e102.
29. Ferreira JC, Mochly-Rosen D. Nitroglycerin use in myocardial infarction patients. Circ J 2012;76: 15-21.
30. Ma H, Yu L, Byra EA, Hu N, Kitagawa K, Nakayama KI, Kawamoto T, Ren J. Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression: role of protein phosphatases. J Mol Cell Cardiol 2010;49: 322-329.
31. Contractor H, Stottrup NB, Cunnington C, Manlhiot C, Diesch J, Ormerod JO, Jensen R, Botker HE, Redington A, Schmidt MR, Ashrafian H, Kharbanda RK. Aldehyde dehydrogenase-2 inhibition blocks remote preconditioning in experimental and human models. Basic Res Cardiol 2013;108: 343.
32. Zhang H, Gong DX, Zhang YJ, Li SJ, Hu S. Effect of mitochondrial aldehyde dehydrogenase-2 genotype on cardioprotection in patients with congenital heart disease. Eur Heart J 2012;33: 1606-1614.
33. Hill BG, Dranka BP, Zou L, Chatham JC, Darley-Usmar VM. Importance of the bioenergetic reserve capacity in response to cardiomyocyte stress induced by 4-hydroxynonenal. Biochem J 2009;424: 99-107.
34. Mak S, Lehotay DC, Yazdanpanah M, Azevedo ER, Liu PP, NewtonGE. Unsaturated aldehydes including 4-OH-nonenal are elevated in patients with congestive heart failure. J Card Fail 2000;6: 108-114.
35. Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N, Banba K, Nagase S, Miyaji K, Morita H, Saito H, Emori T, Ohe T. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 2005;11: 117-123.
36. Churchill EN, Ferreira JC, Brum PC, Szweda LI, Mochly-Rosen D. Ischaemic preconditioning improves proteasomal activity and increases the degradation of deltaPKC during reperfusion. Cardiovasc Res 2010;85: 385-394.
37. Hill BG, Awe SO, Vladykovskaya E, Ahmed Y, Liu SQ, Bhatnagar A, Srivastava S. Myocardial ischaemia inhibits mitochondrial metabolism of 4-hydroxy-trans-2-nonenal. Biochem J 2009;417: 513-524.